# Royalty Pharma plc (RPRX) FY2024 Annual P&L / Income Statement

- Company: Royalty Pharma plc (RPRX)
- Period: 2024-01-01 to 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-12, accession number 0001802768-25-000010
- Page: https://plicit.ai/financials/rprx/fy2024-annual-income-statement
- Chart image: https://plicit.ai/charts/rprx-fy2024-annual-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2024-01-01 through 2024-12-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total income and other revenues**: 2,263,576,000 US dollars
- **Total operating expense, net**: 971,132,000 US dollars
- **Operating income**: 1,292,444,000 US dollars
- **Total other (income)/expense, net**: 38,369,000 US dollars
- **Consolidated net income before tax**: 1,330,813,000 US dollars
- **Income tax expense**: 0 US dollars
- **Consolidated net income**: 1,330,813,000 US dollars
- **Income from financial royalty assets**: 2,149,422,000 US dollars
- **Other royalty income and revenues**: 114,154,000 US dollars
- **Provision for changes in expected cash flows from financial royalty assets**: 732,461,000 US dollars
- **Research and development funding expense**: 2,000,000 US dollars
- **Amortization of intangible assets**: 0 US dollars
- **General and administrative expenses**: 236,671,000 US dollars
- **Financial royalty asset impairment**: 0 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Royalty Pharma plc: $858.98 M; to noncontrolling interests: $471.83 M.